|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 clinical mutations cause myeloproliferative neoplasms and leukemia, and the mutations strongly concentrate in the regulatory pseudokinase domain Janus kinase homology (JH) 2.
|
30092288 |
2019 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 and SRSF2 mutation were not associated with increased leukemia transformation.
|
29970342 |
2018 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While expression of mutant Jak2 was necessary for leukemia induction, neither its continued expression nor enzymatic activity was required to maintain leukemia survival and rapid proliferation.
|
29907650 |
2018 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
|
29940115 |
2018 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In particular, gain-of-function mutations in the <i>JAK</i> genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.
|
29379470 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Survival was longer in JAK2 V617F-unmutated leukaemia (343 days vs. 95 days, P = 0·003).
|
28542718 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative leukemia virus gene is mutated.
|
27686378 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis.
|
28331226 |
2017 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this report, we proposed that miRNA-101 targets Jak2 mRNA and regulates its expression and induces K562 leukemia cell apoptosis.
|
27517565 |
2016 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data support the testing of type II JAK2 inhibition in patients with JAK2-dependent leukemias and other disorders.
|
26175414 |
2015 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Supporting the notion that LT signalling plays a role in T-ALL, inactivation of Ltbr results in a significant delay in TEL-JAK2-induced leukaemia onset.
|
26456771 |
2015 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Having both a tyrosine kinase-activating rearrangement and genomic lesions affecting lymphoid transcription factors suggested that the leukemia was of the Philadelphia chromosome (Ph)/BCR-ABL1-like ALL subtype and that JAK2 inhibitors might be able to overcome this aggressive ALL with SPAG9-JAK2.
|
25951811 |
2015 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SHP1 negatively regulates the Janus kinase 2/signal transducer and activator of transcription (JAK2/STAT) signaling pathway, which is constitutively activated in myeloproliferative neoplasms (MPNs) and leukemia.
|
25824741 |
2015 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ginsenoside Rg1 induces apoptosis through inhibition of the EpoR-mediated JAK2/STAT5 signalling pathway in the TF-1/ Epo human leukemia cell line.
|
24761846 |
2014 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Continued research into how miRNAs impact JAK2(V617F) clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment.
|
23432162 |
2013 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Constitutive activation of Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling has an important role in the oncogenesis of myeloproliferative neoplasms (MPNs) and leukemia.
|
23111066 |
2013 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously showed that CD34⁺/CD38⁻ acute myelogenous leukemia (AML) cells, which contain leukemia stem cells, expressed a greater amount of the phosphorylated forms of JAK2 and STAT5 (p-JAK2 and p-STAT5) than their CD34⁺/CD38⁺ counterparts.
|
23564444 |
2013 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Negative regulation of JAK2 by H3K9 methyltransferase G9a in leukemia.
|
22801367 |
2012 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study was conducted to investigate whether any association exists between genetic polymorphisms in the JAK2, STAT3 and STAT5 genes and individual susceptibility to leukemia.
|
22126101 |
2012 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the presence of mutations in the points most frequent for mutations (hotspot mutations) in phosphatidylinositol-3-kinase (PI3K), Janus kinase 2 (JAK2), FMS-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1), which are involved in leukemia and other cancers, in a population of Brazilian MDS patients.
|
21789382 |
2011 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the thrombopoietin receptor gene (myeloproliferative leukemia, MPL) have been reported in patients with JAK2 V617F-negative chronic myeloproliferative disorders (MPDs).
|
21326037 |
2011 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia.
|
21712540 |
2011 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A search for additional mutations identified alterations of RUNX1, WT1, TP53, CBL, NRAS, and TET2, without significant differences between JAK2-mutant and wild-type leukemias.
|
20008300 |
2010 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tauhese results identify a previously unrecognized nuclear role for JAK2 in the phosphorylation of H3Y41 and reveal a direct mechanistic link between two genes, jak2 and lmo2, involved in normal haematopoiesis and leukaemia.
|
19783980 |
2009 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Essential thrombocythemia: past and present.
|
19636672 |
2009 |